Sign In
23 Nov 2006 10:15
SR Pharma plc
Share issue
London 23 November 2006 - SR Pharma plc (the Company) announces that application has been made for the admission to trading on AIM of 21,636 SR Pharma plc ordinary shares of 1p, with admission expected to take place on 24 November 2006.The shares have been issued following exercise of options by staff at a price of 12.75p per share.
Following the issue of these shares the Company has an issued share capital of 113,064,951 Ordinary Shares of 1p each.
- Ends -
SR Pharma (www.srpharma.com)
SR Pharma plc is a European biopharmaceutical company, listed on AIM. The Company has two operating subsidiaries Atugen AG (www.atugen.com) based in Berlin, Germany and Stanford Rook Ltd based in London, UK.
Atugen is a leader in RNAi therapeutics. This Company has developed novel, chemically modified proprietary siRNA molecules ("AtuRNAi") and a proprietary delivery system ("AtuPLEX") both of which have advantages over conventional siRNA molecules and their delivery systems. Currently Atugen and its collaboration partners have lead molecules in pre-clinical development for a variety of therapeutic indications. Clinical development of AtuRNAi therapeutic molecules for systemic applications in Atugen's oncology programs are targeted to start in 2007. Other clinical AtuRNAi therapeutic programs of Atugen's collaborators are scheduled to commence in 2H 2006.
Stanford Rook Ltd owns a proprietary Mycobacterium vaccae-based technology and related products, and a number of other proprietary immunotherapeutic compounds and related intellectual property. Currently the Company is in discussions with third parties regarding the co-development and out-licensing of M. vaccae and related products.
Forward-Looking Statements
This press release includes forward-looking statements that are subject to risks, uncertainties and other factors. These risks and uncertainties could cause actual results to differ materially from those referred to in the forward-looking statements. All forward--looking statements are based on information currently available to SR Pharma and SR Pharma assumes no obligation to update any such forward-looking statements.
Enquiries:
For further information, please contact the following:
SR Pharma plc Atugen AG +44(0)20 7307 1620 +49(0)30 9489 2800 Iain Ross, Chairman Thomas Christĩly, Chief Executive Officer
Melvyn Davies, Finance Director Dr. Klaus Giese, Chief Scientific
Officer Northbank communication +44(0)20 7886 8150 Sue Charles, Justine Lamond
srpharma@northbankcommunications.com
SR PHARMA PLC
Follow the stocks
